

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 June 2024 (27.06.2024)



(10) International Publication Number
WO 2024/133935 A1

(51) International Patent Classification:

C07K 16/10 (2006.01) *A61K 47/68* (2017.01)
A61K 39/395 (2006.01) *A61P 11/00* (2006.01)
A61K 39/42 (2006.01) *A61P 31/14* (2006.01)
A61K 47/10 (2017.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2023/087731

(22) International Filing Date:

22 December 2023 (22.12.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/476,994 23 December 2022 (23.12.2022) US
23150688.2 09 January 2023 (09.01.2023) EP

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **ABLYNX NV** [BE/BE]; Technologiepark 21,
9052 Zwijnaarde (BE).

(72) Inventors: **BOUTTON, Carlo**; c/o Ablynx N.V., Patent
Department, Technologiepark 21, Gent-Zwijnaarde, 9052
Gent (BE). **CASTEELS, Peter**; c/o Ablynx N.V., Patent
Department, Technologiepark 21, Gent-Zwijnaarde, 9052
Gent (BE). **FERRIER BERTHELOT, Alexandra**; c/o
Sanofi, Patent Department, 46 avenue de la Grande Armée,
75017 PARIS (FR). **PONSAERTS, Raf**; c/o Ablynx N.V.,
Patent Department, Technologiepark 21, Gent-Zwijnaarde,
9052 Gent (BE). **REED, John**; c/o Sanofi, Patent Depart-
ment, 450 Water Street, Cambridge, Massachusetts 02141
(US).

(74) Agent: **HOFFMANN EITLE PATENT- UND
RECHTSANWÄLTE PARTMBB, ASSOCIATION NO.
151**; Arabellastraße 30, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: PROTEIN-BASED CONJUGATION CARRIERS

(57) Abstract: The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least one, preferably at least two, attachment point(s) or conjugation site(s). In particular, the technology provides a molecule comprising at least one protein-based building block, wherein the at least one protein-based building block: a) comprises at least one conjugation site or attachment point; b) has a molecular mass of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg/mL or more, measured in an aqueous solution at room temperature; and does not specifically bind to any human protein or binds one or more human proteins with a K_D value greater than 5×10^{-4} mol/litre.



WO 2024/133935 A1